Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Investments (2022 - 2026)

Indivior Pharmaceuticals has reported Long-Term Investments over the past 5 years, most recently at $27.0 million for Q1 2026.

  • For Q1 2026, Long-Term Investments changed 0.0% year-over-year to $27.0 million; the TTM value through Mar 2026 reached $27.0 million, changed 0.0%, while the annual FY2025 figure was $28.0 million, 3.7% up from the prior year.
  • Long-Term Investments for Q1 2026 was $27.0 million at Indivior Pharmaceuticals, down from $28.0 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $98.0 million in Q4 2022 and troughed at $26.0 million in Q1 2024.
  • A 5-year average of $34.6 million and a median of $27.0 million in 2024 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: crashed 58.16% in 2023 and later rose 7.69% in 2025.
  • Year by year, Long-Term Investments stood at $98.0 million in 2022, then crashed by 58.16% to $41.0 million in 2023, then plummeted by 34.15% to $27.0 million in 2024, then increased by 3.7% to $28.0 million in 2025, then dropped by 3.57% to $27.0 million in 2026.
  • Business Quant data shows Long-Term Investments for INDV at $27.0 million in Q1 2026, $28.0 million in Q4 2025, and $28.0 million in Q3 2025.